the aid library

LIST OPTIONS

Filter

2169

Vigilância global, prevenção e controlo das doenças respiratórias crónicas: uma abordagem integradora

Bousquet, J.; Khaltaev, N. (2007) C_WHO

Chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease, kill more than four million people every year and affect hundreds of millions more. These diseases erode the health and well-being of the patients and have a negative impact on families and societies. Women ... more

Download (82)

View PDF (87)

The silent epidemic of COPD in Africa

Salvi S. The Lancet Global Health (2015) CC2

The article "The silent epidemic of COPD in Africa" discusses the under-recognized yet significant prevalence of chronic obstructive pulmonary disease (COPD) in Africa. Despite being the third leading cause of death worldwide, COPD remains poorly studied and largely unknown in sub-Saharan Africa. Th... more

Download (107)

View PDF (105)

Ambient air pollution and non-communicable respiratory illness in sub-Saharan Africa: a systematic review of the literature

Glenn, B. E.; Espira, L. M.; Larson, M. C.; Larson, P. S. BMC (2022) CC2

Aerosol pollutants are known to raise the risk of development of non-communicable respiratory diseases (NCRDs) such as asthma, chronic bronchitis, chronic obstructive pulmonary disease, and allergic rhinitis. Sub-Saharan Africa’s rapid pace of urbanization, economic expansion, and population growt... more

Download (91)

View PDF (77)

The COPD Foundation - South Africa

The COPD Foundation - South Africa The COPD Foundation - South Africa (2024) CC2

The website for the COPD Foundation in South Africa provides information and resources dedicated to raising awareness, improving education, and supporting individuals affected by Chronic Obstructive Pulmonary Disease (COPD). Managed by the C.A.R.E.S. Group (COPD Advocacy, Research, Education, Suppor... more

Download (96)

View PDF (110)

Household air pollution - WHO

World Health Organisation (WHO) World Health Organization (WHO) (2023) C_WHO

The World Health Organization (WHO) highlights the significant health risks associated with household air pollution, primarily resulting from the use of inefficient and polluting fuels and technologies for cooking, heating, and lighting. In 2020, approximately 2.1 billion people—about one-third of... more

Download (145)

View PDF (224)

Health Advisory for Elderly Population of India during COVID19 Pandemic

Ministery of Health and Family Welfare - Government of India (2020) C2

Elderly people are at a higher risk of COVID-19 infection due to their decreased immunity and body reserves, as well as multiple associated comorbidities like diabetes, hypertension, chronic kidney disease and chronic obstructive pulmonary disease. Also, course of disease tends to be more severe in ... more

Download (356)

View PDF (239)

Safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women

World Health Organization WHO (2021) C_WHO

COVID-19 Vaccines: 1 Safety Surveillance 2 Manual While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregn... more

Download (173)

View PDF (287)

Tuberculosis in Brazil: the impact of the COVID-19 pandemic

Fernandes Maia, C.M.; Barbosa Martelli, D. R.; Mendes L. da Silveira, D. M.; et al. Sociedade Brasileira de Pneumologia e Tisiologia (2022) CC

J Bras Pneumol. 2022;48(2):e20220082 The spread of Severe Acute Respiratory Syndrome - Coronavirus 2 (SARS-CoV-2) continues to progress, causing damage in several countries of the world due to its rapid transmissibility and significant mortality rates, despite government measures to contain its tra... more

Download (344)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Air Pollution - WHO

World Health Organisation (WHO) (2022) C_WHO

Accessed on 06.03.2022 Air pollution is contamination of the indoor or outdoor environment by any chemical, physical or biological agent that modifies the natural characteristics of the atmosphere. Household combustion devices, motor vehicles, industrial facilities and forest fires are common sou... more

External Link

Tuberculoza pulmonară (Rezumat)

Dr. O. Nicolaescu emcb (Educatie medicala continua) (2014) C2

Rezumat. Definiţie. Epidemiologie. Etiologie. Ciclul de transmitere al tuberculozei. Patogenie si imunitate. Leziuni morfologice în tuberculoză.Modul PNEUMOLOGIE 1 mai 2013 – 30 aprilie 2014]Creditat prin decizia CMR nr. 6653/21.12.2012

Download (210)

View PDF (400)

Prevalence of Pulmonary Tuberculosis among Prison Inmates in Ethiopia, a Cross-Sectional Study

S. Ali, A. Haileamlak, A. Wieser, et al. (2015) CC

PLOS ONE 10(12): e0144040. doi:10.1371/journal.pone.0144040

External Link

The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990–2016

India State-Level Disease Burden Initiative CRD Collaborators (2018) CC

Lancet Glob Health 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/S2214-109X(18)30409-1

Download (337)

View PDF (437)

Prevalence and Associated Risk Factors of Pulmonary Tuberculosis among Prisoners in Eastern Ethiopia

D. S. Abebe University of Oslo (2009) C2

Download (170)

View PDF (153)

De Diagnóstico y tratamiento de la enfermedad Pulmonar Obstructiva Crónica Guía de Práctica Clínica Nacional - 2016

Ministerio de Salud Argentina (2016) C2

El objetivo es proveer al equipo de salud, una guía de diagnóstico y terapéutica clínica, tanto farmacológica como no farmacológica, con recomendaciones basadas en evidencia de la mejor calidad disponible y adaptada al marco local. Los usuarios de la Guía son todos los integrantes del ... more

Download (1964)

View PDF (1203)

Clinical Practice Guidelines in the Diagnosis and Management of COPD in the Philippines

Council on COPD and Pulmonary Rehabilitation (2009) C1

Download (2501)

View PDF (788)

Tumor Mediastinum (Tumor Mediastinum Nonlimfoma)

The Indonesian Association of Pulmonologist (2003) C1

Guidelines of Mediastinum Tumor non Lymphoma

Download (162)

View PDF (136)

Guía Clínica - Asma Bronquial en adultos

Ministerio de Salud Chile (2013) C2

Guía Clínica - Asma Bronquial en adultos

Download (732)

View PDF (1956)

Let's talk TB: a free, online book for primary care providers

Madhukar Pai GP clinics (2018) CC

The third edition, released in 2018, has grown to include a total of 18 chapters, contributed by 20 experts and authors from many countries. The goal remains the same: to educate primary care providers on the best practices in TB diagnosis, treatment and follow-up. All articles are richly illustrate... more

Download (340)

View PDF (209)

Standard treatment guidelines medicine (Respiratory Diseases) India

Ministry of Health & Family Welfare, India (2020) C1

Accessed Febr. 6, 2020